Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. NNC0519-0130 appears in 1 tracked Biotech story from February 24, 2026.
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. NNC0519-0130 appears in 1 tracked Biotech story from February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NNC0519-0130. Shared-story counts are live from our verified record — not editorial picks.
Novo Nordisk's experimental triple-G agonist demonstrated nearly 20% weight loss in a 26-week Phase 2 trial, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's mid-stage results, Novo remains on track to reach the market after its rival.
NNC0519-0130 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
